{"id":"https://openalex.org/W4320879652","doi":"https://doi.org/10.1016/j.josat.2023.208980","title":"Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019","display_name":"Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019","publication_year":2023,"publication_date":"2023-02-15","ids":{"openalex":"https://openalex.org/W4320879652","doi":"https://doi.org/10.1016/j.josat.2023.208980","pmid":"https://pubmed.ncbi.nlm.nih.gov/36841074"},"language":"en","primary_location":{"id":"doi:10.1016/j.josat.2023.208980","doi":"https://doi.org/10.1016/j.josat.2023.208980","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.josat.2023.208980","pdf_url":null,"source":{"id":"https://openalex.org/S4387286195","display_name":"Journal of Substance Use and Addiction Treatment","issn_l":"2949-8759","issn":["2949-8759"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","ki-jl-1","medline","norway-1","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Substance Use and Addiction Treatment","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.josat.2023.208980","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006212152","display_name":"Stephen C. Ijioma","orcid":"https://orcid.org/0000-0001-5270-0832","observed_orcids":["https://orcid.org/0000-0001-5270-0832"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4210146161","display_name":"Indivior (United States)","ror":"https://ror.org/04drzaz56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210146161"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen C. Ijioma","raw_affiliation_strings":["Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA; Virginia Commonwealth University, Department of Pharmacotherapy & Outcomes Science, 1112 East Clay Street, Richmond, VA 23298, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA; Virginia Commonwealth University, Department of Pharmacotherapy & Outcomes Science, 1112 East Clay Street, Richmond, VA 23298, USA","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4210146161"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051859508","display_name":"Howard D. Chilcoat","orcid":"https://orcid.org/0000-0001-6715-0044","observed_orcids":["https://orcid.org/0000-0001-6715-0044"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210146161","display_name":"Indivior (United States)","ror":"https://ror.org/04drzaz56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210146161"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard D. Chilcoat","raw_affiliation_strings":["Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA; Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA; Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210146161"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070256460","display_name":"Angela DeVeaugh\u2010Geiss","orcid":"https://orcid.org/0000-0003-1846-552X","observed_orcids":["https://orcid.org/0000-0003-1846-552X"]},"institutions":[{"id":"https://openalex.org/I4210146161","display_name":"Indivior (United States)","ror":"https://ror.org/04drzaz56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210146161"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela M. DeVeaugh-Geiss","raw_affiliation_strings":["Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA. Electronic address: Angela.DeVeaugh-Geiss@indivior.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indivior Inc., 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235, USA. Electronic address: Angela.DeVeaugh-Geiss@indivior.com","institution_ids":["https://openalex.org/I4210146161"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3340,"currency":"USD","value_usd":3340},"apc_paid":{"value":3340,"currency":"USD","value_usd":3340},"fwci":0.8846,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.70310983,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"147","issue":null,"first_page":"208980","last_page":"208980"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/opioid-use-disorder","display_name":"opioid use disorder","score":0.9409999847412109},{"id":"https://openalex.org/keywords/benzodiazepines","display_name":"benzodiazepines","score":0.75},{"id":"https://openalex.org/keywords/opioid-analgesics","display_name":"opioid analgesics","score":0.9769999980926514},{"id":"https://openalex.org/keywords/risk-evaluation-and-mitigation-strategy","display_name":"risk evaluation and mitigation strategy","score":0.8240000009536743},{"id":"https://openalex.org/keywords/source-of-payment","display_name":"source of payment","score":0.5139999985694885},{"id":"https://openalex.org/keywords/medicaid","display_name":"Medicaid","score":0.40299999713897705},{"id":"https://openalex.org/keywords/medicare","display_name":"Medicare","score":0.47200000286102295},{"id":"https://openalex.org/keywords/private-insurance","display_name":"private insurance","score":0.6679999828338623},{"id":"https://openalex.org/keywords/prescribing-trends","display_name":"prescribing trends","score":0.37599998712539673},{"id":"https://openalex.org/keywords/opioid-use-disorder-treatment","display_name":"opioid use disorder treatment","score":0.4020000100135803},{"id":"https://openalex.org/keywords/prescribing-guidelines-adherence","display_name":"prescribing guidelines adherence","score":0.5320000052452087}],"concepts":[{"id":"https://openalex.org/C2778949969","wikidata":"https://www.wikidata.org/wiki/Q407721","display_name":"Buprenorphine","level":4,"score":0.8664983510971069},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8400088548660278},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.778009295463562},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6728008389472961},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6044536232948303},{"id":"https://openalex.org/C2776865356","wikidata":"https://www.wikidata.org/wiki/Q1182681","display_name":"Defined daily dose","level":3,"score":0.48474451899528503},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.46954211592674255},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.4513855576515198},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.4309432804584503},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.259985089302063},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.08190491795539856},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.07397419214248657},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000701","descriptor_name":"Analgesics, Opioid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009293","descriptor_name":"Opioid-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011307","descriptor_name":"Drug Prescriptions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.josat.2023.208980","doi":"https://doi.org/10.1016/j.josat.2023.208980","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.josat.2023.208980","pdf_url":null,"source":{"id":"https://openalex.org/S4387286195","display_name":"Journal of Substance Use and Addiction Treatment","issn_l":"2949-8759","issn":["2949-8759"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","ki-jl-1","medline","norway-1","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Substance Use and Addiction Treatment","raw_type":"journal-article"},{"id":"doi:10.2139/ssrn.4178959","doi":"https://doi.org/10.2139/ssrn.4178959","is_oa":true,"landing_page_url":"https://doi.org/10.2139/ssrn.4178959","pdf_url":null,"source":{"id":"https://openalex.org/S4210172589","display_name":"SSRN Electronic Journal","issn_l":"1556-5068","issn":["1556-5068"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1318003438","host_organization_name":"RELX Group (Netherlands)","host_organization_lineage":["https://openalex.org/I1318003438"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"pmid:36841074","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36841074","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of substance use and addiction treatment","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.josat.2023.208980","doi":"https://doi.org/10.1016/j.josat.2023.208980","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.josat.2023.208980","pdf_url":null,"source":{"id":"https://openalex.org/S4387286195","display_name":"Journal of Substance Use and Addiction Treatment","issn_l":"2949-8759","issn":["2949-8759"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","ki-jl-1","medline","norway-1","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Substance Use and Addiction Treatment","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F3119067897","display_name":"Indivior","ror":null}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1974524186","https://openalex.org/W1992389336","https://openalex.org/W1995188972","https://openalex.org/W2020975316","https://openalex.org/W2031176986","https://openalex.org/W2117063553","https://openalex.org/W2132974770","https://openalex.org/W2314214487","https://openalex.org/W2404633355","https://openalex.org/W2423908661","https://openalex.org/W2582743722","https://openalex.org/W2606089712","https://openalex.org/W2606583128","https://openalex.org/W2759940635","https://openalex.org/W2792562585","https://openalex.org/W2888156742","https://openalex.org/W2889861957","https://openalex.org/W2890254074","https://openalex.org/W2896562901","https://openalex.org/W2961974779","https://openalex.org/W2962856113","https://openalex.org/W2993572872","https://openalex.org/W3000666598","https://openalex.org/W3001657010","https://openalex.org/W3030646380","https://openalex.org/W3036226737","https://openalex.org/W3080552716","https://openalex.org/W3137861665","https://openalex.org/W3139154806","https://openalex.org/W3179112797","https://openalex.org/W3205115907","https://openalex.org/W3206550289","https://openalex.org/W4205211847","https://openalex.org/W4210481981","https://openalex.org/W4220780040","https://openalex.org/W4280525581"],"related_works":["https://openalex.org/W4292182833","https://openalex.org/W4379508111","https://openalex.org/W2576925536","https://openalex.org/W4387612622","https://openalex.org/W4400574798","https://openalex.org/W2402955261","https://openalex.org/W4306958351","https://openalex.org/W3000046303","https://openalex.org/W4311283097","https://openalex.org/W2343964089"],"abstract_inverted_index":{"INTRODUCTION:":[0],"This":[1],"study":[2,187,344],"describes":[3],"utilization":[4],"patterns":[5,22],"of":[6,14,101,134,166,175,195,204,246,306,336],"oral":[7,337],"buprenorphine":[8,77,113,136,338,364],"products":[9],"indicated":[10],"for":[11],"the":[12,28,39,67,173,186,201,343,352],"treatment":[13,36,114,156,182,205,307,339,356],"opioid":[15,105,293,314,368],"use":[16,30,295,326,373],"disorder":[17],"with":[18,24,99,172,279,351],"a":[19,162,191,242,274,360],"focus":[20],"on":[21,61],"consistent":[23,350],"prescribing":[25,347],"guidelines":[26],"and":[27,34,42,63,81,87,161,177,222,241,283,287,292,303,317,329,346,354,365,370],"safe":[29],"conditions":[31],"during":[32],"induction":[33,90],"maintenance":[35,94],"outlined":[37],"by":[38,89],"Risk":[40],"Evaluation":[41],"Mitigation":[43],"Strategy":[44],"(REMS)":[45],"Program,":[46],"including":[47],"trends":[48],"over":[49,185,297,342],"time.":[50],"METHODS:":[51],"Using":[52],"an":[53,132],"anonymized":[54],"longitudinal":[55],"patient-level":[56],"dataset":[57],"that":[58],"captures":[59],"information":[60],"medical":[62],"pharmacy":[64],"claims":[65],"in":[66,200,276,281,285,299,362],"United":[68],"States":[69],"(October":[70],"1,":[71,119],"2014":[72],"through":[73],"March":[74],"31,":[75],"2020),":[76],"prescriptions,":[78],"days'":[79,144,153,179,196],"supply,":[80],"daily":[82,164,223],"dose":[83,165,224],"were":[84,110],"described":[85],"overall":[86],"stratified":[88],"(month":[91,95,210,227,250],"1)":[92],"vs.":[93],"2-6)":[96],"treatment,":[97],"along":[98],"duration":[100],"concomitant":[102,311,325,363,372],"benzodiazepines":[103],"or":[104,313,367],"analgesics.":[106],"RESULTS:":[107],"Overall,":[108],"there":[109,270],"1.5":[111],"million":[112],"episodes":[115,130,308,340],"initiated":[116],"between":[117],"January":[118],"2015":[120,267],"to":[121,207,268,272],"September":[122],"30,":[123],"2019":[124],"(2015:":[125],"258,899;":[126],"2019:":[127],"351,378).":[128],"Treatment":[129],"included":[131],"average":[133],"6.8":[135],"prescriptions":[137,176,247],"(standard":[138],"deviation":[139],"[SD]":[140],"=":[141,149,159,170,214,220,232,239,256,264],"6.7),":[142],"16.8":[143],"supply":[145,154,180,197],"per":[146,155,181,198,225,248,253,261],"prescription":[147,199,226],"(SD":[148,158,169],"10.5),":[150],"94.2":[151],"total":[152,178],"episode":[157,183],"71.4),":[160],"mean":[163,193,244],"13.6":[167],"mg":[168,230,237],"6.3),":[171],"number":[174,194,245,335],"declining":[184],"period.":[188],"There":[189,358],"was":[190,348,359,374],"lower":[192],"first":[202],"month":[203,216,249,254,262],"compared":[206],"months":[208,234,258],"2-6":[209],"1:":[211,228,251],"15.8":[212],"[SD":[213,219,231,238,255,263],"11.0];":[215],"2-6:":[217,235,259],"19.0":[218],"10.1])":[221],"13.3":[229],"6.4];":[233],"14.3":[236,304],"6.2]),":[240],"higher":[243],"2.5":[252],"1.7];":[257],"1.8":[260],"1.2]).":[265],"From":[266],"2019,":[269,300],"appeared":[271],"be":[273],"shift":[275],"payer":[277],"mix,":[278],"increases":[280],"Medicaid/Medicare":[282],"declines":[284],"cash":[286],"commercial":[288],"insurance.":[289],"Concomitant":[290],"benzodiazepine":[291,312,366],"analgesic":[294],"declined":[296],"time;":[298],"16.6":[301],"%":[302,305,319,328],"had":[309,320],"any":[310],"analgesic,":[315],"respectively,":[316],"<5":[318],"chronic":[321,371],"(>90":[322],"overlapping":[323],"days)":[324],"(3.0":[327],"0.4":[330],"%,":[331],"respectively).":[332],"CONCLUSIONS:":[333],"The":[334],"increased":[341],"period,":[345],"generally":[349],"REMS":[353],"other":[355],"guidelines.":[357],"decline":[361],"analgesics,":[369],"rare.":[375]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2023-02-16T00:00:00"}